Amidst the global battle against the COVID-19 pandemic, researchers are exploring a promising avenue for treatment: N-acetylglucosamine (GlcNAc). While remdesivir has been established as a standard care in emergency use, GlcNAc is now under investigation as a first-line treatment for coronavirus-positive patients. This development not only offers hope in combating the pandemic but also opens up...
English
Arabic
French
Spanish
Portuguese
Deutsch
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek